SCHEMBL21484883

SCHEMBL21484883

N#CCC(=O)Nc1nc(-c2ccc(Br)s2)cs1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.64
KDM4E B2RXH2 4/20 0.64
ABL1 P00519 3/20 0.64
POLB P06746 1/20 0.64
MEN1 O00255 8/20 0.54
KMT2A Q03164 8/20 0.54
MAPT P10636 6/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
ALDH1A1 P00352 3/20 0.54
NPC1 O15118 3/20 0.54
RAB9A P51151 3/20 0.54
GAA P10253 2/20 0.49
HDAC8 Q9BY41 3/20 0.47
HDAC1 Q13547 2/20 0.44
HTT P42858 4/20 0.44
ESR1 P03372 1/20 0.44
HSP90AA1 P07900 1/20 0.44
MDM2 Q00987 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484876 0.86 ABL1 (0.59) LMNAKDM4EABL1POLBMEN1
SCHEMBL21484823 0.85 ABL1 (0.58) LMNAKDM4EABL1POLBMEN1
SCHEMBL21484734 0.81 ABL1 (0.69) LMNAKDM4EABL1MEN1KMT2A
SCHEMBL21484844 0.81 MEN1 (0.66) LMNAKDM4EABL1MEN1KMT2A
SCHEMBL21484842 0.79 ABL1 (0.57) LMNAKDM4EABL1MEN1KMT2A
SCHEMBL16434479 0.79 ABL1 (1.00) LMNAKDM4EABL1POLBMEN1
SCHEMBL21484713 0.78 ABL1 (0.68) LMNAKDM4EABL1MEN1KMT2A
SCHEMBL21484835 0.78 ABL1 (0.68) KDM4EABL1MEN1KMT2AMAPT
SCHEMBL16434470 0.76 LMNA (0.71) LMNAKDM4EABL1POLBMEN1
SCHEMBL16434543 0.76 LMNA (0.59) LMNAKDM4EABL1POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
CN-112313229-A Substituted aminothiazoles as inhibitors of nucleases 马萨里克大学 2021-02-02 CN disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 LMNA 522/4885KDM4E 1848/4885ABL1 2243/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 LMNA 522/4885KDM4E 1848/4885ABL1 2243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.